Elon Musk Backs mRNA As Moderna's Stock Soars on Cancer Vaccine Win - Moderna (NASDAQ:MRNA)

Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)

Moderna and Merck posted the first Phase 3 success for individualized mRNA cancer therapy (intismeran + Keytruda), marking mRNA's pivot from COVID vaccines to personalized oncology. This unlocks a multi-billion ecosystem—genomics, AI diagnostics, sequencing—potentially extending Keytruda's $31.7B revenue and reshaping precision-medicine investment thesis.